Trial Profile
Avonex Fifteen Year Long Term Follow Up of Patients With Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ASSURANCE
- 15 Apr 2010 Multiple Sclerosis Severity Scale outcomes presented at the 62nd Annual Meeting of the American Academy of Neurology.
- 07 Oct 2008 Status changed from active, no longer recruiting to completed.
- 19 Sep 2008 Data presented at the World Congress on Treatment and Research in Multiple Sclerosis.